Pathway inhibition was also sustained for 24 h in the Pan02 line (Figure 3E), confirming the ability of Azeliragon to disrupt RAGE-mediated NF-κB activation in pancreatic cancer cell lines. This evidence concerns the gene NFKB1 and familial pancreatic carcinoma.